Authors: MICHAEL M OZA A EGORIN MJ PATNAIK A FIRBY P SIU LL LITCHMAN M MOORE MJ

Citation: M. Michael et al., PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) ANALYSIS OF A PHASE-I STUDY OF TAXOL((R))(T), CARBOPLATIN (C) WITH P-GLYCOPROTEIN (P-GP) MODULATOR PSC-833 (PSC), Annals of oncology, 9, 1998, pp. 621-621

Authors: ADVANI R SABA HI TALLMAN M ROWE JM WIERNIK PH RAMEK J DUGAN K LUM B VILLENA J SIKIC BI DAVIS E PAIETTA E LITCHMAN M GREENBERG P

Citation: R. Advani et al., TREATMENT OF POOR-PROGNOSIS AML WITH PSC833 PLUS MITOXANTRONE, ETOPOSIDE, CYTARABINE (PSC-MEC), Blood, 90(10), 1997, pp. 2260-2260

Authors: ADVANI R SABA H ROWE JM TALLMAN M WIERNIK P RAMEK J DUGAN K LITCHMAN M DORR R LUM B SIKIC B DAVIS E PAIETTA E GREENBERG P

Citation: R. Advani et al., TREATMENT OF REFRACTORY RELAPSED AML WITH PSC833 PLUS MITOXANTRONE, ETOPOSIDE, CYTARABINE (PSC-MEC)/, Blood, 88(10), 1996, pp. 847-847

Authors: LIST AF KARANES C DORR R SPIER C GROGAN T GREER J MOORE J WEINBERGER J SCHILLER G DALTON W PEARCE T LITCHMAN M

Citation: Af. List et al., MODULATION OF ANTHRACYCLINE RESISTANCE IN POOR-RISK ACUTE MYELOID-LEUKEMIA (AML) WITH SDZ PSC-833 - RESULTS OF A PHASE I II MULTICENTER STUDY/, Blood, 88(10), 1996, pp. 1156-1156